
    
      This phase 2, single-arm, open-label study using pacritinib will treat patients with
      histologically confirmed prostate adenocarcinoma, status post definitive treatment and
      biochemical recurrence.

      The primary objective of this study is to determine the effect of pacritinib on the time to
      prostate-specific antigen (PSA) progression in patients with biochemical relapse of prostate
      cancer (defined as the length of time that a given subject will be alive and free from PSA
      progression per Prostate Cancer Working Group 3 (PCWG3) guidelines.
    
  